Health Condition 1: null- secondary pulmonary hypertension
Conditions
Interventions
Intervention1: Sildenafil: Sildenafil was given in dose of 20 mg three times a day for 6 week orally.
Control Intervention1: Placebo: Placebo was given in controlled arm.
Control Intervention2: Placeb
Sponsors
Department of cardiology King george medical university
Eligibility
Inclusion criteria
Inclusion criteria: Patients with symptomatic secondary pulmonary hypertension with New York Heart Association (NYHA) functional class II-III with underlying aetiologies of pulmonary hypertension such as valvular heart disease, dilated cardiomyopathy, heart failure with preserved ejection fraction, chronic obstructive pulmonary disease and interstitial lung disease were included in the study.
Exclusion criteria
Exclusion criteria: Patients with primary pulmonary hypertension, hypotension, allergy to sildenafil, ischemic heart disease, on other vasodilators (ex. Nitrate), prior treatment with other anti PAH drugs, prior cardiac valve surgery, severe valve stenosis were excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement (improvement in 6 minute walk test, and NYHA functional class)Timepoint: at the end of 6 week | — |
Secondary
| Measure | Time frame |
|---|---|
| (i) the change from baseline to week 6 in haemodynamic and biochemical parameters PASP, LVEF, RV function, and NT-Pro BNP level; (ii) safety and tolerability.Timepoint: at the end of 6 week | — |
Countries
India
Contacts
Public ContactPrashant Dwivedi
king georges medical university
Outcome results
None listed